Roche wins Japan approval for personalized cancer drug Rozlytrek #España #Sevilla #Valencia #Barcelona #Madrid

7.9 MTM Advertisements:

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo

ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.

Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumors, across 10 different tumor types, including those with central nervous system metastases.

Reporting by John Miller; Editing by Michelle Martin

Our Standards:The Thomson Reuters Trust Principles.

Siga este enlace para la fuente del contenido y las imágenes. Todos los derechos están reservados por los propietarios. Para cualquier cambio o reproducción de este contenido, por favor, póngase en contacto con los propietarios de este artículo aquí.

9.2 AAP MTM Advertisements:

Patina Yungs


No comments!

There are no comments yet, but you can be first to comment this article.

Leave reply

Your email address will not be published. Required fields are marked *